We are live on ! Find out more
CGON icon

CG Oncology
CGON

96 hedge funds and large institutions have $1.7B invested in CG Oncology in 2024 Q1 according to their latest regulatory filings, with 96 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

88.84% more ownership

Funds ownership: 0% → 88.84% (+89%)

45% less call options, than puts

Call options by funds: $48K | Put options by funds: $88K

Holders
96
Holders Change
+96
Holders Change %
–
% of All Funds
1.38%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.07%
New
96
Increased
–
Reduced
–
Closed
–
Calls
$48K
Puts
$88K
Net Calls
-$40K
Net Calls Change
-$40K

Top Buyers

Rank Fund Capital Flow
1
DC
Decheng Capital
California
+$223M
2
TCM
TCG Crossover Management
California
+$146M
3
BlackRock
BlackRock
New York
+$103M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$90.9M
5
BI
BVF Inc
California
+$77M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
DC
1
Decheng Capital
California
$240M +$223M +5,458,810 New
TCM
2
TCG Crossover Management
California
$157M +$146M +3,570,206 New
BlackRock
3
BlackRock
New York
$111M +$103M +2,518,550 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$97.7M +$90.9M +2,225,018 New
BI
5
BVF Inc
California
$82.7M +$77M +1,884,191 New
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$66.8M +$62.1M +1,521,432 New
APM
7
Avidity Partners Management
Texas
$63.9M +$59.4M +1,454,765 New
RCM
8
RA Capital Management
Massachusetts
$61.3M +$57.1M +1,397,433 New
PA
9
Perceptive Advisors
New York
$57.3M +$53.3M +1,304,105 New
B
10
Braidwell
Connecticut
$49.6M +$46.2M +1,130,235 New
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$43.6M +$40.5M +992,118 New
AllianceBernstein
12
AllianceBernstein
Tennessee
$40.8M +$38M +929,752 New
AWGLSCP
13
ABG-WTT Global Life Science Capital Partners
Hong Kong
$40.2M +$37.4M +915,501 New
Franklin Resources
14
Franklin Resources
California
$37.2M +$34.6M +848,092 New
CAM
15
Cormorant Asset Management
Massachusetts
$35.1M +$32.7M +800,000 New
FLSM
16
Frazier Life Sciences Management
California
$33.8M +$31.4M +770,000 New
Holocene Advisors
17
Holocene Advisors
New York
$33.7M +$31.3M +766,625 New
PCH
18
Polar Capital Holdings
United Kingdom
$32M +$29.8M +729,166 New
T. Rowe Price Investment Management
19
T. Rowe Price Investment Management
Maryland
$31.1M +$28.9M +708,711 New
ACA
20
Avoro Capital Advisors
New York
$30.7M +$28.6M +700,000 New
FCMV
21
Foresite Capital Management V
California
$30.4M +$28.3M +692,550 New
Millennium Management
22
Millennium Management
New York
$24.5M +$22.8M +558,197 New
WP
23
Woodline Partners
California
$23.1M +$21.4M +525,199 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$22.1M +$20.6M +504,216 New
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$20M +$18.6M +455,000 New
1
2 3 4

CGON Hedge Fund Activity: Q1 2024 in Review

96 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q1 2024, worth a combined $1.7B.

Buyers outnumbered sellers: 96 funds opened new CGON positions and 0 closed out — a net gain of 96 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Decheng Capital, opening a new position worth an estimated $223M.

  • 96 institutional investors held CG Oncology (CGON) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $1.7B of CG Oncology stock for Q1 2024.
  • 96 funds opened new CG Oncology positions in Q1 2024 and 0 closed out, a net change of +96 holders.
  • The largest CG Oncology buyer in Q1 2024 was Decheng Capital, an estimated $223M added.

Based on aggregated 13F filings for Q1 2024.